Gene transfer with recombinant adenoviruses (rAds) is a powerful means of inducing an immune response against a transgene product. However, little is known about the mechanisms that underlie the induction of the immune response after intramuscular inoculation of adenovirus and, in particular, the relative role of the different cell types transduced. Several studies have suggested that CD8 + cytotoxic T lymphocyte responses elicited after inoculation of adenoviruses (Ads) are induced both by direct transduction of antigen presenting cells (APCs) and by cross-priming. In the present study, a library of fibre-chimeric rAds was screened in order to identify rAds with distinct capacities to express transgene product in murine cell types naturally found in muscle, i.e. myoblasts, endothelial cells (both representing non-APCs) and dendritic cells (representing APCs). Four selected pseudotypes, differing in their ability to infect muscular cells were used to immunize C57BL/6 mice. The relationship between the capacity to transduce non-APC or APC in vitro and the ability to induce humoral and cellular responses against the b-galactosidase antigen after intramuscular inoculation were studied. Results indicate that CD8 + T cell responses against the b-galactosidase antigen were similar after inoculation of the four viruses, thus revealing no direct relationship with their ability to transduce myoblasts, endothelial cells or dendritic cells in vitro.
INTRODUCTION
Recombinant adenoviruses (rAds) are currently widely used as vectors for gene therapy and vaccination. Gene transfer with rAds is a powerful means of inducing humoral and cellular responses against a transgene product (Juillard et al., 1995; Tripathy et al., 1996; Yang et al., 1996) . Among the administration routes tested, the intramuscular route (i.m.) is one of the most potent. This approach has been used to develop adenoviral-based vaccines for several infectious diseases and cancers in different animal models (Branger et al., 2001; Shiver et al., 2002) . On the other hand, the immune response against the transgene product is a limiting factor in the use of rAds as vectors for gene therapy purposes, for which stable expression of the transgene product is desired (Dai et al., 1995) . Thus, gaining an understanding of the mechanism underlying the induction of the immune response against the transgene product, and notably the relative role of the different cell types transduced after rAd inoculation, would be of great benefit. This information is crucial not only for the design of vaccine strategies to optimize immune responses against rAd-encoded transgene products, but also for gene therapy, as it may be possible to modulate the immune responses by targeting specific cell types. In a previous study we have shown that the transduction of different cell types present in the muscle; myoblasts, endothelial cells and dendritic cells (DCs), could participate in the induction of an antibody response against the transgene product after rAd i.m. inoculation. Moreover, we had shown that transduction of DCs, which are the most potent antigen-presenting cells (APCs), was necessary to induce a strong and protective CD8 + T cell response against a rAd-encoded transgene product after i.m. inoculation (Mercier et al., 2002) . The CD8 + cytotoxic T lymphocyte (CTL) response is the main effector of the immune system to eliminate virus infected-cells (Barry & Bleackley, 2002) . Recognition of infected cells is mediated by the interaction of the T cell receptor on CTL with virus-derived peptides, in the context of major histocompatibility complex class I (MHC I) molecules. Antigens (Ags) can be presented to CD8 + CTL through the classical MHC I pathway (direct priming), by which endogenous Ags localized in the cytoplasm of transduced cells are degraded into peptides that are presented in association with MHC I molecules on the cell surface. In addition exogenous Ags, which are not expected to gain access to the cytoplasm of an APC, are presented on MHC I molecules by the exogenous or cross-priming pathway (Heath & Carbone, 2001; Gromme & Neefjes, 2002) . The relative contribution of these two pathways in inducing CD8 + CTL is important for understanding the mechanisms of induction of the immune response after rAds gene transfer. Several studies have suggested that CD8 + CTL responses are induced both by direct transduction of APCs and by cross-priming from other cell types transduced by rAds (Jooss et al., 1998; Sarukhan et al., 2001) . In muscle, myoblasts (satellite cells), which are non-APC, are transduced after i.m. inoculation of rAd (Quantin et al., 1992) and may act as a source of transgene product for a crosspriming pathway. Similarly, endothelial cells, which are widely represented in muscle and are efficiently transduced by rAd vectors, could be a source of Ags for transfer to APCs (Lemarchand et al., 1992) . Since these cells express MHC I and MHC II as well as costimulatory molecules in vitro, human endothelial cells have been proposed to act as APCs under some conditions, such as inflammation. However, in contrast to human endothelial cells, studies have shown that murine endothelial cells are unable to stimulate the proliferation of CD4 + T cells or activation of CD8 + T cells (Marelli-Berg et al., 2000 .
Attachment and entry of numerous human Ads, except those belonging to subgroup B, depend on the binding of the viral fibre protein to a high-affinity Ad receptor, i.e. the coxsackie-adenovirus receptor (CAR) (Bergelson et al., 1997; Tomko et al., 1997) . After fibre binding, interaction between the Arg-Gly-Asp (RGD) sequence present in the viral penton base and a v integrins present on the host cell triggers the internalization of the virus in clathrin coated pits (Wickham et al., 1993) .
Several studies have demonstrated that the fibre protein carried by rAds can be modified so as to alter tropism in vitro (Barnett et al., 2002) . Since different Ads display different tropisms (Horwitz, 1996) , one approach to modify the tropism of rAds is to replace the entire fibre protein of one serotype with that of another, thus generating pseudotyped rAds (Wickham et al., 1997) . Such replacement, however, may give rise to unstable recombinant vectors. Therefore, replacing only a portion of the fibre is preferred. In this manner, Rea et al. (2001) have shown that pseudotyped rAds carrying fibres from human subgroup B Ads were able to transduce human DCs more efficiently than rAd5 (Rea et al., 2001) . Very few studies, however, have compared the ability of these pseudotyped rAds to induce an immune response against the transgene product in vivo.
In the present study, we have used a library of pseudotyped, fibre-chimeric rAds with the aim (i) to identify vectors with distinct capacities to express transgene product in murine cell types naturally present in the muscle and (ii) to identify whether such distinct transgene product expression patterns could influence the ability of such viruses to induce potent immune responses against the transgene in vivo. Hereto, pseudotyped vectors selected on the basis of their differential ability to express transgene in murine myoblasts, endothelial cells and DCs were injected i.m. into C57BL/6 mice.
METHODS
Pseudotyped viruses. The generation and purification of fibrechimeric adenoviral vectors on PER.C6 cells have been described previously Rea et al., 2001) . Briefly, viruses produced in four T175 triple-layer tissue culture flasks were purified with a two-step caesium chloride purification protocol. After purification, viruses were aliquoted and stored at 280 uC. The virus titres expressed in virus particles (VP) per ml were determined by highpressure liquid chromatography (HPLC) (Shabram et al., 1997) . All rAds were deleted for the E1 region. Because of a frameshift in the E3 10?4 kDa protein, the RID complex is not functional in these viruses. The expression cassette contains a CMV promoter and SV40 poly-(A) signal. Fibre-chimeric rAds encoding the luciferase (Luc) reporter gene and expressing fibres from adenovirus subgroup B (11, 35, 50) , C (5), D (9, 10, 13, 24, 27, 30, 33, 38) and F (40L) were used for transduction experiments. Pseudotyped rAds encoding the b-galactosidase protein (bGal) and carrying fibre of serotype 5, 35, 40L and 50 were used for in vivo experiments. A rAd5 carrying no transgene was used as a negative control for in vivo experiments.
Cell lines and cell culture. Primary mouse myoblasts were kindly provided by C. Pinset and D. Montarras (Pasteur Institute, Paris, France). Cells were cultivated in medium composed of high-glucose DMEM and MCDB 202 medium (1 : 1, v/v) (both from BICEF, l'Aigle, France) supplemented with 20 % FCS (Biomedia) and 2 % (v/v) Ultroser (Biosepra). Endothelial cells derived from mouse heart and immortalized with SV40 T antigen were provided by D. Paulin and C. Delouis (Vicart et al., 1994) . These cells were grown in DMEM containing 10 % FCS (Invitrogen). RMA-S cells are lymphoid cells that were cultivated in RPMI (Invitrogen) with 10 % FCS. Primary murine DCs were generated from bone marrow of C57BL/6 mice as described previously (Lutz et al., 1999) . Briefly, total bone marrow leukocytes were plated in bacteriological Petri dishes in RPMI medium containing 10 % FCS and recombinant murine granulocyte-colony-stimulating factor (20 ng ml 21 ) at 2610 6 cells per plate. The medium was partially replaced every 2 to 3 days. On day 8 of in vitro culture, non-adherent cells were used for transduction. Chinese hamster ovary (CHO) cells stably transfected with either cDNA constructs encoding human coxsackie and adenovirus receptor (CHO-CAR cells) or with vector alone (CHO-pcDNA) were cultured in MEM (Invitrogen) with 10 % FCS (Bergelson et al., 1997) . All media were supplemented with L-glutamine (2 mM), penicillin (50 IU ml 21 ), streptomycin (50 mg ml 21 ) and sodium pyruvate (1 mM). Cells were cultured at 37 uC in a 5 % CO 2 incubator, except endothelial cells, which were cultured in an 8 % CO 2 incubator.
Attachment experiments with fibre-chimeric rAds. Binding of fibre-chimeric rAds to CHO-pcDNA and CHO-CAR was assayed by flow cytometry. Hereto, 5610 5 cells were incubated for 1 h at 4 uC at different ratios of VP per cell in 50 ml of PBS. After washing twice with PBS, cells were incubated with a monoclonal antibody, 1D2, specific for the Ad penton base protein (Hong et al., 2000) for 30 min on ice and then with a 1 : 15 dilution of goat antimouse immunoglobulin coupled to phycoerythrin (DAKO). Following additional washes in PBS, cells were fixed in 400 ml of 1 % paraformaldehyde (PFA) and analysed by flow cytometry.
Transduction and analysis of gene transfer. Transduction experiments using rAds were performed in triplicate in 96-well plates with each well containing approximately 5610 4 cells in serum-free medium. Transduction experiments on myoblasts, endothelial cells and DCs were performed at 1000, 5000 and 8000 VP per cell, respectively. CHO-pcDNA and CHO-CAR cells were incubated with increasing ratios of VP per cell (ranging from 20 to 2500 VP per cell). Cells were exposed to virus for 2 h at 37 uC. The inoculum was then replaced by fresh complete medium. Gene transfer efficiency was assessed 24 (for CHO-CAR and CHO-pcDNA) or 48 h later (for DCs, myoblasts and endothelial cells) by measurement of Luc activity with commercially available reagents (luciferase reporter gene assay; Roche Diagnostics) using a Berthold luminometer (Lumat LB 9507) for DCs, myoblasts and endothelial cells and a Thermo Labsystems luminometer (Fluoroskan ascent FL) for CHO-CAR and CHO-pcDNA.
Blocking experiments. For blocking experiments, transduction assays on myoblast and endothelial cells were performed with 1000 or 5000 VP per cell, respectively, in the presence of 10 % rabbit polyclonal antiserum against recombinant soluble CAR (Spiller et al., 2002) or of a control rabbit polyclonal serum in a final volume of 50 ml. Cells were exposed to the virus for 2 h at 37 uC and then fresh complete medium was added. Gene transfer efficiency was assessed 24 h later using a Thermo Labsystems luminometer (Fluoroskan ascent FL).
Immunization with rAds or rAd-transduced DCs. Female C57BL/6 mice, 6 weeks of age, were purchased from Iffa Credo (L'Arbresle, France). Animals were handled in accordance with the institutional guidelines of the National Veterinary School of Alfort. Groups of seven mice were injected by the i.m. route at one site in the quadriceps with 50 ml of inoculum. The inoculum was either 10 8?5 or 10 10 VP of rAd5 or fibre-chimeric rAd vectors, or 2610 4 bGal-expressing DCs (transduced either with rAd5bGal or with rAdF35bGal at 25 000 VP per cell) or control DCs. Viral DNA contained in each rAd inoculum was quantified by real-time PCR. Peripheral blood was collected at the indicated time points. For all analyses, blood samples were pooled from animals in the same group.
Anti-bGal antibody assay. Anti-bGal plasma antibody titres were determined by ELISA. A 96-well plate (Maxisorb; Nunc) was coated overnight at 4 uC with 500 ng of bGal (Roche Diagnostic) in 100 ml of 0?1 M Tris, 2 mM EDTA, 0?15 M NaCl (pH 9?6) buffer. A solution containing 0?1 % (v/v) Tween 20 and 0?5 % (w/v) gelatin in PBS was used as a blocking buffer. The plate was washed with 0?05 % Tween 20 in water, and dilutions of plasma were incubated in the coated wells for 30 min at 37 uC. Secondary antibodies were as follows: goat anti-mouse IgG (Amersham Biosciences), antimouse IgG1 (Caltag Laboratories) and anti-mouse IgG2a (Caltag Laboratories). The peroxidase (POD) activity was analysed by using BM-Blue POD as a substrate. Absorbance was measured at 405 nm. Preimmune sera were used to determine the background level.
Anti-IFN-c ELISPOT assay. The interferon gamma (IFN-c) ELISPOT assay was performed as described previously (Mercier et al., 2002) . Briefly, 96-well nitrocellulose plates (Multiscreen HA; Millipore) were incubated overnight at 4 uC with 40 ng of antimouse IFN-c monoclonal antibody (MAb) R4-6A2 (PharMingen) per well. Wells were washed repeatedly with culture medium and saturated with complete medium for 30 min at 37 uC. MHC I compatible target cells, RMA-S cells, were pulsed with a synthetic peptide (40 mg ml 21 ) representing the CD8 + epitope [ICPMYARV; I8V (Isochem)] of bGal in the H-2 b haplotype (Oukka et al., 1996) . Serially diluted PBMC (1610 6 -1?25610 5 ) were co-cultured with 10 5 pulsed RMA-S in the ELISPOT wells, in medium supplemented with recombinant human interleukin 2 (30 IU ml 21 ) (Roche Molecular Biochemicals), for 24 h at 37 uC under 5 % CO 2 . After extensive washing with PBS/0?05 % Tween 20, plates were incubated overnight at 4 uC with 50 ng per well of biotinylated anti-mouse IFN-c Mab XMG1.2 (PharMingen) and then with ExtrAvidin alkaline phosphatase conjugate (Sigma) for 1 h at room temperature. Spots were developed by an alkaline phosphatase conjugate substrate (Bio-Rad Laboratories). The number of spots, corresponding to IFN-c secreting cells, was determined with a KS-ELISPOT (Zeiss-Kontron).
Statistical analysis. Statistical analysis was carried out using single factor ANOVA. Comparisons of means were performed at P<0?05. Computations were done using the SAS statistical software package.
RESULTS
Gene transfer into distinct cell types present in muscle using fibre-chimeric rAds
In order to identify rAds with different capacities to express transgene product in cell types naturally present in the muscle, we performed transduction experiments involving a library of 13 rAds encoding the Luc reporter protein and expressing fibres from Ad subgroup B (11, 35, 50) , C (5), D (9, 10, 13, 24, 27, 30, 33, 38) and F (40L). Myoblasts, endothelial cells and DCs were transduced with 1000, 5000 or 8000 VP per cell, respectively. Gene transfer efficiency was evaluated by measuring Luc activity 48 h later. The rAd5 and the rAd carrying the long fibre of serotype 40 (rAdF40L) were efficient in expressing transgene product in myoblasts and endothelial cells ( Fig. 1A and B ). Flow cytometry analyses have shown that these two cell types express the murine CAR homologue (data not shown). At the doses of viruses used, the Luc activity measured with rAdF40L and rAd5 was similar in myoblasts and endothelial cells, i.e. 10 6 relative light units (RLU) per 10 4 cells, and proved significantly higher than the activity measured with the other fibre-chimeric rAds (P<0?05). In contrast, all rAds express transgene product inefficiently in mouse DCs, even at a dose of 8000 VP per cell. While the Luc activity detected in these cells was always less than 10 4 RLU per 10 4 cells, significant differences were observed between certain viruses. For example, in three independent experiments, the Luc activity measured with rAdF35 in DCs was 20 times higher than that measured with rAdF50 (P<0?05), as shown in Fig. 1(C) .
Based on these findings we selected four viruses presenting different in vitro patterns of transgene product expression in muscle cell type for in vivo experiments. These included rAd5 and rAdF40L, shown to express transgene product in endothelial cells and myoblasts at a high level, rAdF35 shown to express transgene product only in DCs as efficiently as rAd5, and rAdF50, shown to express transgene product in these three cell types inefficiently.
rAds binding to and transduction of CHO-pcDNA and CHO-CAR
To compare selected pseudotyped viruses with rAd5 as regards to their mechanisms of attachment and internalization, binding and transduction assays were performed using two different CHO cell lines, i.e. CHO-CAR, stably transfected with a vector expressing CAR and CHO-pcDNA, transfected with the empty vector. The binding of rAd5, rAdF40L, rAdF35 and rAdF50 was evaluated by flow cytometry at seven different ratios of VP per cell (156, 312, 625, 1250, 2500 , 5000 and 10 000 VP per cell). Both rAd5 and rAdF40L bound efficiently to the CHO-CAR cell line ( Fig. 2A) . In contrast, rAdF50 bound very weakly to these cells, and no attachment of rAdF35 to CHO-CAR could be detected, even at the highest ratio tested. Of the four rAds, only rAdF50 bound to CHO-pcDNA to a similar extent as to CHO-CAR cells, indicating that the serotype 50 fibre bound to a receptor other than CAR expressed by both CHO-pcDNA and CHO-CAR cells.
To monitor the infectivity of the different rAd vectors in cells either expressing or not expressing CAR, we compared the transduction efficiency of rAdF40L, rAdF50, rAdF35 and rAd5, all encoding the Luc reporter gene, in CHO-pcDNA and CHO-CAR cell lines (20-2500 VP per cell). The results of these transduction studies demonstrated that CHO-CAR was transduced more efficiently with rAd5 and rAdF40L, resulting in a Luc activity approximately 200 times higher than that with rAdF50 and rAdF35 (Fig. 2B ). In agreement with published data, we found that the transduction efficiency of rAd5 was, on average, 160 times higher in CHO-CAR than in CHO-pcDNA.
By using blocking experiments, we determined that an anti-CAR polyclonal serum could significantly inhibit rAd5 internalization in myoblasts and endothelial cells (P<0?05), although part of the transduction efficiency might be mediated by a CAR independent pathway in endothelial cells (Fig. 2C ) inoculation of fibre-chimeric rAds C57BL/6 mice were inoculated by the i.m. route with rAdF40L, rAdF50, rAdF35 and rAd5, all carrying the lacZ transgene encoding bGal. Blood samples were collected from immunized mice at days 10, 18, 35 and 42 after inoculation. Serum samples from seven mice of each group were pooled and assayed for anti-bGal antibodies by ELISA (Fig. 3) . Mice inoculated with 10 10 VP of each of the four viruses developed similar and high anti-bGal IgG titres at day 42 (Fig. 3A) . In animals inoculated with rAdF50bGal a slower antibody response was seen, which was even more pronounced when mice were inoculated with a lower dose of the different fibre-chimeric rAds (10 8?5 VP) (Fig. 3B) . The slower kinetics of the IgG response may be explained by the lower level of bGal protein expression by this virus in mouse cells, which should reflect lower transduction efficiency in vivo, compared with the other viruses. To determine whether differences between the vectors could be observed at the level of Th1 or Th2 induction, the production of IgG2a and IgG1 was investigated, which is characteristic for Th1-and Th2-dominant conditions, respectively. All four rAds elicited both IgG1 and IgG2a after i.m. injection (Fig. 3C) , indicating that both Th1 and Th2 subsets were activated by all four viruses.
Induction of a bGal-specific CD8+ T cell response by fibre-chimeric rAds
To analyse the capacity of fibre-chimeric rAds (rAdF40LbGal, rAdF50bGal, rAdF35bGal and rAd5bGal) to induce a specific cellular immune response against bGal in C57BL/ 6 mice, we used an IFN-c ELISPOT assay, which correlates with the CD8 + T cell response (Mercier et al., 2002) . Freshly expanded PBMC, isolated 10 and 42 days after a single i.m. immunization with 10 10 VP, were examined for their ability to secrete IFN-c in vitro in response to the H-2 b restricted bGal peptide (I8V) presented by RMA-S target cells. Fig. 4 shows representative results from two independent experiments. Both at day 10 and 42 after inoculation, numbers of IFN-c secreting cells were not significantly different in mice inoculated with the four fibre-chimeric rAds (P>0?05), although levels were higher at day 42 than at day 10. Similar results were obtained after inoculation with a dose of 10 8?5 VP (data not shown).
To study the influence of the fibre on the capacity of transduced DCs to induce a CD8 + T cell immune response against bGal, C57BL/6 mice were inoculated i.m. with 2610 4 lacZ-positive DCs 48 h after transduction with rAd5bGal or rAdF35bGal in vitro. Significant differences in the CD8 + T cell response elicited by DCs transduced with the two viruses were not observed by IFN-c ELISPOT assay on day 40 after the inoculation (P>0?05) (Fig. 5) . These results indicated that the two viruses carrying distinct fibres were able to transduce murine DCs and also to induce their maturation in such a way that the same stimulation of CD8 + T cells was evidenced in vivo.
DISCUSSION
Many studies have demonstrated the efficiency of rAds as vaccine vectors. It is now well documented that the in vivo expression of transgenes via rAd-mediated gene transfer results in a strong cellular and humoral immune response against the transgene after i.m. injection (Klonjkowski et al., 1999) . Moreover, antigen presentation by DCs is a key event in the initiation of the immune response in vivo (Banchereau et al., 2000) . We have recently shown by transduction of endothelial cells, myoblasts and DCs with rAds in vitro, and subsequent grafting of transduced cells in vivo, that only grafting transduced DCs resulted in the induction of a potent CD8 + T cell response (Mercier et al., 2002) . However, it is not known how distinct cell tropism may influence the ability of rAds to induce potent immune responses against the transgene in vivo.
We first used a classical approach that involves studying the ability of viruses to express a transgene product in vitro in targeted cell types, and notably in DCs, before testing them in vivo in animal experiments (Fontana et al., 2003; Brandao et al., 2003; Wang et al., 2003) . In such an approach, each virus of a fibre-chimeric rAds library was first tested for its ability to express the transgene product after in vitro transduction of cell types present in skeletal muscle (endothelial cells, myoblasts and DCs). These experiments led to the selection of four viruses that were used to study the influence of distinct in vitro expression patterns on the ability of these viruses to induce potent immune responses against the transgene product in vivo. We selected rAd5 and rAdF40L, which were highly efficient at expressing the transgene product in myoblasts and endothelial cells in vitro, rAdF35, which was able to express transgene product as efficiently as rAd5 only in DCs, and rAdF50, which was very inefficient at expressing the transgene product in any of the three cell types. It was notable that none of the fibre-chimeric viruses tested in this study appeared to express the transgene product in murine DCs more efficiently than rAd5, although Rea et al. (2001) observed that human DCs were transduced more readily with rAd35 than with rAd5 (Rea et al., 2001) . It is well known that human monocyte-derived DCs do not express CAR, which serves as a high-affinity receptor for the Ad fibre protein and mediates attachment of subgroup C Ads, such as Ad2 and Ad5, to the majority of permissive human cell types (Bergelson et al., 1997) . Moreover, the results obtained in our study indicate (based on transgene expression levels) that murine DCs do not express a high affinity receptor for any of the fibre-chimeric viruses tested. It is noteworthy that the three rAds tested carrying a subgroup B fibre (rAdF11, rAdF35 and rAdF50) expressed the transgene product in murine DCs with markedly different efficiencies. In particular, rAdF11 and rAdF35 transduced these cells 15 to 20 times more efficiently than Fig. 4 . IFN-c secreting cells in mice inoculated with fibrechimeric rAds. The number of bGal-specific IFN-c secreting cells in mice immunized with 10 10 VP of rAd5bGal, rAdF35bGal, rAdF40LbGal or rAdF50bGal was determined using an ELISPOT assay. PBMC isolated at (A) day 10 and (B) Day 42 p.i. were incubated for 24 h with target RMA-S cells pulsed with bGalspecific peptide (I8V). Data represent the mean from three wells. Mice inoculated with rAd5nul (rAd5 carrying no transgene) were used as a negative control. Error bars on the graphs represent standard errors of the mean. rAdF50 (P<0?05). It is well-documented that human subgroup B Ads use a fibre receptor distinct from CAR. This subgroup has been divided into B1 (Ad3, Ad7, Ad50) and B2 (Ad11 and Ad35) species, which present different tropisms in vivo (De Jong et al., 1999) . It has recently been demonstrated that on human cells there are two different receptors for subgroup B Ads, one common to B1 and B2 species and the other exclusively used by the B2 species (Segerman et al., 2003a) . Also, CD46 has been identified as a receptor for Ad11 (Segerman et al., 2003b) . Since rAdF11 and rAdF35 transduce DCs more efficiently than rAdF50, it is possible that murine DCs express a B2 receptor.
The immunization of C57BL/6 mice by the i.m. route with all of the selected fibre-chimeric rAds induced strong antibody responses, but with different kinetics of IgG production. Resting B cells can be stimulated to proliferate and differentiate into antibody-producing cells by a combination of cell contact and soluble signals provided by activated primed helper T (Th) cells. In this study, we observed that the inoculation of rAd5bGal, rAdF40LbGal, rAdF50bGal and rAdF35bGal induced both IgG1 and IgG2a at similar levels. As the isotype profile is guided mostly by cell-secreted cytokines, we postulate that the four viruses induced a similar cytokine profile in vivo. Thus, the replacement of the Ad5 fibre with one derived from either subgroup B or F did not prevent activation of both Th1 and Th2 subsets, classically obtained also after rAd5 inoculation in C57BL/6 mice. In our experiments, the bGal antigen has a nuclear targeting signal and thus is a cell-associated protein. In order to stimulate the B cell response, the newly synthesized bGal protein, after rAd-mediated transduction, needs to be released into the extracellular environment, for instance by the induction of cytotoxic NK and T cell responses (Yang et al., 1996) . The different kinetics of the IgG response observed after inoculation of 10 8?5 VP per mice may be explained by a difference in the level of bGal expression after i.m. inoculation of the different fibre-chimeric rAds, which should reflect different transduction efficiencies in vivo (Huard et al., 1995) . For example, a recent study has described that the rAdF35 induces lower transgene expression than rAd5 in muscle after i.m. inoculation in C57BL/6 mice (Sakurai et al., 2003) . Here we show that rAd5 and rAdF40L, which efficiently express transgene product in myoblasts and endothelial cells in vitro, induced a predominantly faster antibody response than rAdF35 and rAdF50. Many studies have shown that myoblasts are efficiently transduced after i.m. inoculation of rAd and may serve as a reservoir of transgene in vivo. In fact, rAd5 and rAdF40L were similarly efficient in inducing an anti-bGal antibody response. Interestingly, these two fibrechimeric rAds were able to transduce cells via a CARdependant pathway, as shown by CHO-CAR/CHO-pcDNA transduction experiments. Moreover, CAR is involved in myoblast and endothelial cell transduction by rAd5, as shown by using blocking experiments with an anti-CAR polyclonal serum. Together, these data suggest that the induction of the anti-bGal antibody response, after i.m. inoculation in C57BL/6 mice, might be increased following gene delivery by rAds able to induce high levels of transgene product expression, notably by transducing the cells via a CAR dependent mechanism.
It has been previously shown that Ad5 is able to elicit a CD8 + T cell response through both the direct transduction and cross-priming of DCs (Jooss et al., 1998) . A key question that remains is whether one pathway is dominant over the other. In our hands, some viruses (rAd5 and rAdF40L) were much more efficient than others (rAdF35 and rAdF50) in expressing transgene product in murine heart endothelial cells and myoblasts in vitro, but were not more efficient in eliciting a CD8 + T cell response against the transgene product than rAdF35 and rAdF50. Thus, our results suggest that cross-priming from dead or living cells expressing high level of transgene product (Ramirez & Sigal, 2002) is not a key event in eliciting a CD8 + T cell response, in contrast with the major role of cross-priming for the induction of CD8 + immune responses against vaccinia virus following i.m. injection (Shen et al., 2002) . Another possibility is that low levels of expression of foreign proteins in non-APCs are sufficient to establish cross-priming. The latter hypothesis is unlikely however, since it has been demonstrated that only high level of Ag expression allows efficient cross-presentation (Kurts et al., 1998) . Of the four viruses selected for the in vivo experiments, the efficiency of transgene product expression was much less divergent in mouse bone marrow-derived DCs (between 1?15 and 20) than in endothelial cells (between 1?05 and 1800) and myoblasts (between 1?4 and 350), even though the DCs were transduced at a higher m.o.i. This limited divergence did not substantially modify the induction of a CD8 + T cell response in vivo. It is therefore probable that only a small number of transgene productexpressing DCs or a low level of transgene product expression is required for induction of such a response after inoculation of rAds. Timares et al., (1998) have shown that transfection of 500 DCs is sufficient to initiate a wide variety of immune responses in vivo. Nevertheless, it is still not known whether these responses represent an upper limit, or whether more efficient transduction of DCs could lead to a higher CD8 + T cell response against the transgene product. Immunization of C57BL/6 mice with bGal-expressing DCs after ex-vivo transduction with either rAd5 or rAdF35 induced the same anti-bGal CD8 + T cell response. These results indicated that the fibre replacement itself does not alter the ability of rAdtransduced DCs to present foreign Ags and that these two viruses could probably induce the maturation of murine DCs to allow an efficient stimulation of CD8 + T cells. Previously, fibre-and thus receptor-independent transduction of Ad5 in the muscle has been described (Einfeld et al., 2001; van Deutekom et al., 1999) . Receptorindependent uptake of adenoviruses in muscle could also explain the similar T cell responses with the four fibre-chimeric rAds, despite their distinct cellular tropisms observed in vitro. To discriminate between those possibilities, further studies on which cell types are transduced in vivo are required.
The results of the experiments described do not show a direct correlation between the in vitro tropism and the level of the immune response induced after i.m. administration of different fibre-chimeric rAds. Furthermore, we did not find any evidence for significant participation of cross-priming in the development of the CD8 + T cell response against the transgene product. Further studies, including in vivo tropism of these fibre-chimeric adenoviruses, should help in further unravelling the underlying mechanisms for immune induction after i.m. administration.
